TABLE 3.
Genotype and allele frequencies of SNPs were compared between the present study and a previous report ( PharmGKB, 2021) (cont.).
| SNP-ID | Gene | Genotype | n | Identified frequency (%) | Allele | Allele frequency in the present study (%) | Allele frequency in the previous report (%) | HWE p-value |
|---|---|---|---|---|---|---|---|---|
| CYP2A6*4 | CYP2A6 | non*4/non*4 | 54 | 85.7 | non*4 | 92.9 | 95.3 | 0.28 |
| non*4/*4 | 9 | 14.3 | *4 | 7.1 | 4.7 | |||
| *4/*4 | 0 | 0 | ||||||
| rs28399433 | CYP2A6 | A/A | 43 | 68.3 | A | 81.7 | 86.4 | 0.19 |
| A/C | 17 | 27.0 | C | 18.3 | 13.6 | |||
| C/C | 3 | 4.8 | ||||||
| rs1799853 | CYP2C9 | C/C | 63 | 100 | C | 100 | 99.8 | 0.95 |
| C/T | 0 | 0 | T | 0 | 0.2 | |||
| T/T | 0 | 0 | ||||||
| rs1057910 | CYP2C9 | A/A | 57 | 90.5 | A | 94.4 | 95.6 | 0.44 |
| A/C | 5 | 7.9 | C | 5.6 | 4.4 | |||
| C/C | 1 | 1.6 | ||||||
| rs28371759 | CYP3A4 | A/A | 60 | 95.2 | A | 97.6 | 98.5 | 0.17 |
| A/G | 3 | 4.8 | G | 2.4 | 1.5 | |||
| G/G | 0 | 0 | ||||||
| rs776746 | CYP3A5 | A/A | 5 | 7.9 | A | 32.5 | 27.8 | 0.27 |
| A/G | 31 | 49.2 | G | 67.5 | 72.2 | |||
| G/G | 27 | 42.9 | ||||||
| rs10264272 | CYP3A5 | G/G | 63 | 100 | G | 100 | 100 | 1.00 |
| G/A | 0 | 0 | A | 0 | 0 | |||
| A/A | 0 | 0 | ||||||
| rs41303343 | CYP3A5 | −/− | 63 | 100 | no-insT | 100 | 100 | 1.00 |
| -/T | 0 | 0 | insT | 0 | 0 | |||
| T/T | 0 | 0 | ||||||
| rs1057868 | POR | C/C | 26 | 41.3 | C | 65.1 | 59.9 | 0.29 |
| C/T | 30 | 47.6 | T | 34.9 | 40.1 | |||
| T/T | 7 | 11.1 |
HWE, Hardy–Weinberg equilibrium; insT, insertion T.